ENTITY
Hangzhou Tigermed Consulting (A)

Hangzhou Tigermed Consulting (A) (300347 CH)

97
Analysis
Health CareChina
Hangzhou Tigermed Consulting Company Limited provides professional clinical research services for domestic and foreign pharmaceutical and health-related research and development. The Company's main services include clinical trial technology services, data management, and statistical analysis.
more
Refresh
06 Sep 2021 22:26

Novotech Health IPO: A Solid Start to 2021

We examine the PHIP which discloses the 1Q21 results along with additional disclosures and recent developments. Overall, we continue to maintain...

Logo
317 Views
Share
04 Sep 2021 22:37

Novotech Health IPO Initiation: On-Demand Science

Novotech is set to pre-market an HKEx IPO to raise up to $1.5 bn. Novotech’s fundamentals are solid and the IPO is worth a look for investors...

Logo
289 Views
Share
27 Jul 2021 10:03

Asymchem Labs A/H Listing Early Look - Fast Growing, Relatively Insulated

Asymchem Laboratories (002821 CH) (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong. The A-shares listed were listed in...

Logo
206 Views
Share
bullishWuxi Biologics
20 Jul 2021 18:54

Wuxi Biologics Placement - Similar Deal Will Yield Similar Results

Wuxi Biologics Holdings is looking to raise up to US$1.3bn by selling about 1.8% of Wuxi Biologics (2269 HK). This is the company's 15th placement...

Logo
349 Views
Share
25 Feb 2021 17:41

JOINN Laboratories IPO: Trading Debut

The grey market price varies from HK$146.70-HK$142.00 per H-share vs listing price of HK$151. JOINN is fairly priced at the H-share listing price...

Logo
363 Views
Share
x